Katja Grosse-Sender

Title: Katja Grosse-Sender: Innovator in Pharmaceutical Sciences

Introduction

Katja Grosse-Sender is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of novel solid forms of compounds used in medical treatments. With a total of 3 patents to her name, her work is recognized for its potential impact on viral disease treatment.

Latest Patents

Her latest patents focus on the solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate. These inventions relate to pharmaceutical compositions that may serve as TLR7 agonists, which are crucial for the treatment or prophylaxis of viral diseases, particularly those associated with HBV infection.

Career Highlights

Katja Grosse-Sender is currently employed at Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. Her innovative work has positioned her as a key figure in the development of new therapeutic solutions.

Collaborations

Throughout her career, she has collaborated with notable colleagues, including Urs Schwitter and Xuemei Wang. These partnerships have further enhanced her research and development efforts in the pharmaceutical field.

Conclusion

Katja Grosse-Sender's contributions to pharmaceutical sciences through her patents and collaborations highlight her role as an influential inventor. Her work continues to pave the way for advancements in the treatment of viral diseases.